Table 1. Summary of studies that assessed LNG-IUS use in perimenopausal women.

Disease	Study	Study design	No. of subjects	Main results
Heavy menstrual bleeding	Yoo et al. [16]	Retrospective	192	80.7% success rate of LNG-IUS
				13.5% women failed with LNG-IUS
	Desai [17]	Prospective observational	40	33 women continued to use LNG-IUS
	Küçük and Ertan [18]	RCT	44 (DMPA), 44 (MPA 5 mg daily), 44 (LNG-IUS)	LNG-IUS, superior to DMPA and MPA in PBAC scores and hemoglobin levels
Non-atypical endometrial hyperplasia	Abu Hashim et al. [24]	RCT	60 (LNG-IUS), 60 (NET)	Higher regression rate in LNG-IUS group
				Higher hysterectomy rate in NET group (57.4% vs. 22%)
	Haimovich et al. [25]	Open, prospective	15	Regression rate at 12 months: 100%
Uterine fibroids	Machado et al. [27]	Prospective observational	60	At 24 months, hysterectomy avoidance rate, 89.5%

LNG-IUS: levonorgestrel-intrauterine system, RCT: randomized controlled trial, DMPA: depo-medroxyprogesterone acetate, MPA: medroxyprogesterone acetate, PBAC: pictorial blood loss assessment, NET: norethisterone acetate.